- Home
- CCD vs BBNX Comparison
CCD vs BBNX Comparison
Compare CCD & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCD | BBNX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 629.2M | 620.3M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | CCD | BBNX |
|---|---|---|
| Price | $22.76 | $13.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $27.58 |
| AVG Volume (30 Days) | 96.1K | ★ 1.6M |
| Earning Date | 01-01-0001 | 02-17-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,570,000.00 |
| Revenue This Year | N/A | $53.88 |
| Revenue Next Year | N/A | $34.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.01 |
| 52 Week Low | $16.93 | $8.89 |
| 52 Week High | $24.68 | $32.71 |
Technical Indicators
Market Signals| Indicator | CCD | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 58.99 | 28.81 |
| Support Level | $21.88 | $13.40 |
| Resistance Level | $22.78 | $14.95 |
| Average True Range (ATR) | 0.39 | 1.07 |
| MACD | -0.06 | 0.18 |
| Stochastic Oscillator | 75.23 | 19.76 |
Price Performance
Historical ComparisonAbout CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.